Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) Target Price at $19.30

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $14.50.

Several analysts have recently commented on NEO shares. Leerink Partners lowered shares of NeoGenomics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $25.00 to $9.00 in a research report on Wednesday. Leerink Partnrs lowered NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. The Goldman Sachs Group cut their price objective on NeoGenomics from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Morgan Stanley lowered their target price on shares of NeoGenomics from $17.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday.

NeoGenomics Stock Up 6.1 %

Shares of NASDAQ:NEO opened at $7.70 on Tuesday. NeoGenomics has a 52-week low of $6.08 and a 52-week high of $19.12. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The business has a fifty day moving average of $9.40 and a two-hundred day moving average of $13.26. The stock has a market cap of $990.66 million, a P/E ratio of -12.42 and a beta of 1.41.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm had revenue of $168.04 million during the quarter, compared to analysts’ expectations of $171.38 million. During the same period in the prior year, the company posted ($0.02) EPS. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year. On average, research analysts expect that NeoGenomics will post -0.2 earnings per share for the current year.

Institutional Trading of NeoGenomics

A number of institutional investors and hedge funds have recently bought and sold shares of NEO. Vanguard Group Inc. grew its holdings in shares of NeoGenomics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company’s stock valued at $234,673,000 after purchasing an additional 195,793 shares in the last quarter. Greenhouse Funds LLLP boosted its position in NeoGenomics by 5.3% in the 4th quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company’s stock valued at $77,487,000 after buying an additional 237,491 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of NeoGenomics by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company’s stock worth $56,645,000 after acquiring an additional 78,211 shares in the last quarter. First Light Asset Management LLC increased its position in shares of NeoGenomics by 3.0% during the fourth quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company’s stock worth $52,202,000 after acquiring an additional 91,030 shares during the period. Finally, Segall Bryant & Hamill LLC raised its stake in shares of NeoGenomics by 11.2% in the first quarter. Segall Bryant & Hamill LLC now owns 2,350,746 shares of the medical research company’s stock valued at $22,309,000 after acquiring an additional 236,924 shares in the last quarter. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.